Cargando…

异基因造血干细胞移植后肾小球肾炎六例临床分析

OBJECTIVE: To explore the occurrence, clinical characteristics, diagnosis and treatment of glomerulitis after allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: Analysis were carried out based on the clinical data of 6 patients with de novo glomerulitis following allo-HSCT hosp...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342261/
https://www.ncbi.nlm.nih.gov/pubmed/30369188
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.09.011
_version_ 1783555423717031936
collection PubMed
description OBJECTIVE: To explore the occurrence, clinical characteristics, diagnosis and treatment of glomerulitis after allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: Analysis were carried out based on the clinical data of 6 patients with de novo glomerulitis following allo-HSCT hospitalized in Henan Tumor Hospital from January 2008 to December 2016, and the clinical manifestation, pathology, diagnosis, treatment and outcome were investigated. RESULTS: The occurrence of glomerulitis was 1.26% (6/478). The median time was 447(272–1 495) d after allo-HSCT. Proteinuria and varying degrees of edema were present in all patients. Of the 6 patients, 4 patients with impaired renal function, 3 cases of hypertension, 5 cases of urine occult blood positive, 2 cases of hyperlipidemia. 5 patients underwent acute graft-versus-host disease (GVHD), 4 patients accompanied with chronic GVHD at diagnosis. Kidney pathology showed typical features of minimal change diseases in 1 patient, membranous nephropathy in 4 patients and mesangial proliferative glomerulonephritis in 1 case. Immunohistochemistry of glomerular lesions revealed that the immune complex deposition included IgG in 4 patients, C3 in 3 patients, IgM and C1q in 1 patient. Serum ANA was positive in 2 patients and serum IgG and IgM were in high level in 1 patient, respectively. Only 1 case was effective on glucocorticoid. 5 cases treated by low dose cyclophosphamide combined with mycophenolate mofetil (MMF), 2 cases achieved complete remission, and 3 cases were partial remission. Up to now, 2 cases died with lung infection, and 4 patients survived. CONCLUSION: The predominant pathological type of glomerulitis was membranous nephropathy. Low-dose cyclophosphamide combined with MMF was an effective treatment.
format Online
Article
Text
id pubmed-7342261
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73422612020-07-16 异基因造血干细胞移植后肾小球肾炎六例临床分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore the occurrence, clinical characteristics, diagnosis and treatment of glomerulitis after allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: Analysis were carried out based on the clinical data of 6 patients with de novo glomerulitis following allo-HSCT hospitalized in Henan Tumor Hospital from January 2008 to December 2016, and the clinical manifestation, pathology, diagnosis, treatment and outcome were investigated. RESULTS: The occurrence of glomerulitis was 1.26% (6/478). The median time was 447(272–1 495) d after allo-HSCT. Proteinuria and varying degrees of edema were present in all patients. Of the 6 patients, 4 patients with impaired renal function, 3 cases of hypertension, 5 cases of urine occult blood positive, 2 cases of hyperlipidemia. 5 patients underwent acute graft-versus-host disease (GVHD), 4 patients accompanied with chronic GVHD at diagnosis. Kidney pathology showed typical features of minimal change diseases in 1 patient, membranous nephropathy in 4 patients and mesangial proliferative glomerulonephritis in 1 case. Immunohistochemistry of glomerular lesions revealed that the immune complex deposition included IgG in 4 patients, C3 in 3 patients, IgM and C1q in 1 patient. Serum ANA was positive in 2 patients and serum IgG and IgM were in high level in 1 patient, respectively. Only 1 case was effective on glucocorticoid. 5 cases treated by low dose cyclophosphamide combined with mycophenolate mofetil (MMF), 2 cases achieved complete remission, and 3 cases were partial remission. Up to now, 2 cases died with lung infection, and 4 patients survived. CONCLUSION: The predominant pathological type of glomerulitis was membranous nephropathy. Low-dose cyclophosphamide combined with MMF was an effective treatment. Editorial office of Chinese Journal of Hematology 2018-09 /pmc/articles/PMC7342261/ /pubmed/30369188 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.09.011 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
异基因造血干细胞移植后肾小球肾炎六例临床分析
title 异基因造血干细胞移植后肾小球肾炎六例临床分析
title_full 异基因造血干细胞移植后肾小球肾炎六例临床分析
title_fullStr 异基因造血干细胞移植后肾小球肾炎六例临床分析
title_full_unstemmed 异基因造血干细胞移植后肾小球肾炎六例临床分析
title_short 异基因造血干细胞移植后肾小球肾炎六例临床分析
title_sort 异基因造血干细胞移植后肾小球肾炎六例临床分析
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342261/
https://www.ncbi.nlm.nih.gov/pubmed/30369188
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.09.011
work_keys_str_mv AT yìjīyīnzàoxuègànxìbāoyízhíhòushènxiǎoqiúshènyánliùlìlínchuángfēnxī
AT yìjīyīnzàoxuègànxìbāoyízhíhòushènxiǎoqiúshènyánliùlìlínchuángfēnxī
AT yìjīyīnzàoxuègànxìbāoyízhíhòushènxiǎoqiúshènyánliùlìlínchuángfēnxī
AT yìjīyīnzàoxuègànxìbāoyízhíhòushènxiǎoqiúshènyánliùlìlínchuángfēnxī
AT yìjīyīnzàoxuègànxìbāoyízhíhòushènxiǎoqiúshènyánliùlìlínchuángfēnxī
AT yìjīyīnzàoxuègànxìbāoyízhíhòushènxiǎoqiúshènyánliùlìlínchuángfēnxī
AT yìjīyīnzàoxuègànxìbāoyízhíhòushènxiǎoqiúshènyánliùlìlínchuángfēnxī
AT yìjīyīnzàoxuègànxìbāoyízhíhòushènxiǎoqiúshènyánliùlìlínchuángfēnxī
AT yìjīyīnzàoxuègànxìbāoyízhíhòushènxiǎoqiúshènyánliùlìlínchuángfēnxī
AT yìjīyīnzàoxuègànxìbāoyízhíhòushènxiǎoqiúshènyánliùlìlínchuángfēnxī
AT yìjīyīnzàoxuègànxìbāoyízhíhòushènxiǎoqiúshènyánliùlìlínchuángfēnxī
AT yìjīyīnzàoxuègànxìbāoyízhíhòushènxiǎoqiúshènyánliùlìlínchuángfēnxī